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Objective: To evaluate the role of synovial oxidative stress on joint pathology in a spontaneous mouse
model of osteoarthritis (OA) by intra-articular (IA) delivery of recombinant adeno-associated virus (rAAV)
expressing anti-oxidant protein heme oxygenase-1 (HO-1).
Methods: Joint transduction by rAAV vectors was evaluated with serotype 1, 2, 5 and 8 capsids carrying LacZ
gene administered by IA injections into STR/ort mice. Transduced cell types were identiﬁed by b-galac-
tosidase staining in sectioned joints. Effect of oxidative stress on AAV transduction of primary synoviocytes
in vitrowas quantitated by ﬂuorescence-activated cell sorting (FACS) analysis. In vivo, the efﬁcacy of rAAV1/
HO-1 was tested by IA administration into STR/ort mice followed by histopathological scoring of cartilage.
Levels of 3-nitrotyrosine (3-NT) and HO-1 were assessed by immunohistochemistry (IHC) of joint sections.
Results: Administration of a rAAV1 based vector into OA mouse joints resulted in transduction of the
synovium, joint capsule, adipocytes and skeletal muscle while none of the serotypes showed signiﬁcant
cartilage transduction. All OA joints exhibited signiﬁcantly elevated levels of oxidative stress marker,
3-NT, in the synovium compared to OA-resistant CBA-strain of mice. In vitro studies demonstrated that
AAV transgene expression in primary synoviocytes was augmented by oxidative stress induced by H2O2
and that a rAAV expressing HO-1 reduced the levels of oxidative stress. In vivo, HO-1 was increased in the
synovium of STR/ort mice. However, delivery of rAAV1/HO-1 into OA joints did not reduce cartilage
degradation.
Conclusions: AAV-mediated HO-1 delivery into OA joints during active disease was not sufﬁcient to
improve cartilage pathology in this model.
 2012 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.Introduction
Osteoarthritis (OA) is a painful joint disease characterized by
cartilage degradation, mild synovial inﬂammation and changes in
bone, ligaments and tendons1,2. Currently treatment consists of
pain management as there are no clinically approved disease
modifying agents. Therapeutics that can be delivered directly into
the joint space offer the advantage of providing a high local
concentration at the disease site while reducing the potential for
adverse effects often associated with systemic delivery. Viral
vectors such as adeno-associated virus (AAV) delivered into theS. Kyostio-Moore, Genzyme,
ingham, MA 01701, USA.
m (S. Kyostio-Moore).
s Research Society International. Pintra-articular (IA) joint space can allow local production of ther-
apeutics from transduced tissues and have shown efﬁcacy in animal
models of rheumatoid arthritis (RA)3e8.
An understanding of in vivo tissue tropism of AAV serotypes is
important in the evaluation and application of therapeutic gene
delivery. Multiple studies have demonstrated that AAV capsid
tropism varies depending on tissue type, species or disease
state3,6,9,10. In normal rat joints, AAV2 targeted fat pad, ligaments
and meniscus while in RA, mostly synovial tissues in the supra-
patellar regionwere transduced5e8. Investigation of additional AAV
serotypes for gene transfer in RA joints has shown that AAV5-based
vectors transduced synovium more efﬁciently than those with
AAV1 and 2 capsids7. Evaluation of AAV transduction in equine
chondrocytes and synoviocytes in vitro demonstrated that AAV2,
AAV3 and AAV6were superior to AAV1, AAV5 and AAV811. However,
in vitro culture conditions rarely mimic cell surface receptor
expression and biological barriers presented in in vivo conditions.ublished by Elsevier Ltd. All rights reserved.
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have been reported.
Oxidative stress is elevated in cartilage and synovial tissues in
human OA and in animal models of OA and likely contributes to
disease ampliﬁcation by increasing production of inﬂammatory
mediators and matrix degrading enzymes1,12e14. The free radical
burden by reactive oxygen species (ROS) is further increased
by concomitant down-regulation of various anti-oxidant
proteins1,15,16. A recent clinical study also highlighted the role of
synovial oxidative stress in OA pathology by revealing a correlation
between synovitis and cartilage degradation17. Thus, treatment of
joints with anti-oxidants may reduce synovial inﬂammation with
potential decrease in cartilage degradation. This was shown by
systemic up-regulation of heme oxygenase-1 (HO-1), a proteinwith
anti-oxidant, anti-inﬂammatory and cytoprotective properties in
RA models18e21. Though HO-1 has not been tested in OA models, it
reduced inﬂammatory pathways and production of matrix metal-
loproteases in OA synoviocytes and chondrocytes in vitro22,23.
Our study objectives were to evaluate (1) tissue tropism of
recombinant AAV (rAAV) vectors in mouse OA joints after IA
delivery, (2) the degree and location of oxidative stress in vivo and
its effect on AAV transduction in vitro and (3) the effect of local
expression of HO-1 on cartilage degradation. To address the latter,
HO-1 gene was delivered by rAAV into the joints of STR/ort
mice, a spontaneous model of OA. These mice exhibit many
characteristics of human OA including cartilage degradation, low-
grade synovial inﬂammation, bone remodeling and oxidative
stress1,13,14,24,25.
Methods
Construction of rAAV vectors
The LacZ expression plasmid contained a human cytomegalo-
virus (CMV) promoter, E. coli b-galactosidase (b-gal) gene (LacZ)
and a bovine growth hormone (BGH) polyadenylation signal
(polyA). The enhanced green ﬂuorescence protein (EGFP) vectors
contained CMV enhancer-chicken b-actin (CBA) promoter. Human
(h) HO-1 cDNA (OriGene Technologies) was cloned into an
expression cassette containing a CMV promoter and an SV40 polyA.
A negative control, empty vector (EV) contained non-coding DNA
followed by BGH and SV40 polyA. All expression cassettes were
cloned as single-stranded vectors into a plasmid pAAVSP70 con-
taining AAV type 2 inverted terminal repeats (ITRs)26. AAV
recombinant vectors were generated by triple transfection as
described26. Pseudotyped AAV vectors were obtained by cross-
packaging genomes into AAV1, AAV2, AAV5 or AAV8 capsids10.
The vectors were puriﬁed by iodixanol gradient and resulting
vector titers were quantitated by real time Taqman PCR assay (ABI
Prism 7700) using primers speciﬁc to either BGH or SV40 polyA.
Values were expressed as DNAse resistant particles (drps) per ml27.
In vitro experiments
Primary synoviocytes were dissected from rabbit knee joints
and digested with 0.5 mg/ml collagenase at 37C overnight in
Dulbecco’s modiﬁed Eagle’s media (DMEM). Isolated synoviocytes
were cultured in DMEM supplementedwith 10% fetal bovine serum
(FBS), 100 IU/ml penicillin and 100 mg/ml streptomycin in a 5% CO2
incubator at 37C until conﬂuent. To test the effect of H2O2 on AAV
transduction of primary synoviocytes, cells were plated at
3 105 cells/well in high glucose DMEMwith 10% FBS and 50 mg/ml
gentamicin sulfate. Cells were infected the next day with
1 105 drp/cell AAV2/EGFP for 2.5 h. Media was changed and H2O2
(30% stock, Sigma Aldrich) at concentrations 50 and 100 mM wasadded for 2 h to the cells followed by fresh media change. The cells
were harvested 3 days later and ﬁxed in 1% paraformaldehyde (PFA)
followed by ﬂuorescence-activated cell sorting (FACS) analysis
(FACScalibur ﬂow cytometry; FlowJo Software). Cell viability was
analyzed by trypan blue staining (100, 200 and 300 mM H2O2
resulted in 100, 50 and 20% viability, respectively). To measure the
effect of H2O2 on intracellular ROS levels, cells were harvested using
0.25% trypsin, washed with phosphate buffered saline (PBS) and
resuspended into PBS containing 10 mM of cell permeable ROS
indicator 30-(p-aminophenyl) ﬂuorescein (APF; Invitrogen). After
incubation for 2 h, the cells werewashedwith PBS followed by FACS
analysis using excitation/emission maxima at 490/515 nm. All
tissue culture reagents were purchased from Invitrogen.
HO-1 production from AAV1/HO-1 was conﬁrmed by infecting
1105 293 cells (Stratagene) with 1106 drp AAV1/cell for 2 h. Cell
lysates and conditioned media were harvested 72 h later and
analyzed for HO-1 levels by enzyme-linked immunosorbent assay
(ELISA) (Stressgen) according to manufacturers’ instructions. To test
the ability ofHO-1 to block ROSaccumulation, 293 cellswere infected
for 24 h as described above, media changed and cells cultured for
additional 48 h. The cells were then treatedwith 100 mMH2O2 for 2 h
and assayed for APF ﬂuorescence by FACS as described above.
Animal studies
Male STR/ort (Harlan Laboratories Inc) and CBA mice (Harlan
Laboratories Inc) were housed individually and fed standard irra-
diated rodent chow and water ad libitum. For serotype evaluation,
AAV/LacZ or AAV/1/EV vectors were administered by IA route into
stiﬂe joints of 21e26 week-old STR/ort and CBA mice (eight joints/
group; randomized by age). Under appropriate pain medication,
the shaved and cleaned joints in a ﬂexed position were injected
with 6 ml (3 1010 drp/joint) of virus using a Hamilton syringe with
a 30-gauge needle. Five weeks later, mice were euthanazed by CO2
asphyxiation. Hind knees were skinned and harvested and the
patellar tendon was cut to expose the joint space followed by
staining for b-galactosidase activity. For evaluation of HO-1 gene
delivery as a therapeutic approach to OA, AAV1/EV and AAV1/HO-1
vectors were injected into joints of 13e15 week-old mice with
5  1010 drp rAAV/joint (10e12 joints/group; four joints for AAV1/
LacZ) as described above. Animals were sacriﬁced 3 months later
(at 25e27 weeks of age) by cervical dislocation and joints were
collected for histological analysis. Studies were approved by the
Genzyme Institutional Animal Care and Use Committee (IACUC)
and conducted in accordance with humane guidelines for animal
care and use.
Joint processing and histological evaluation
For AAV/LacZ studies, skinned joints were tied onto histology
cassettes, ﬁxed with 2% PFA in 0.1 M NaHPO4, pH 7.4 for 1 h and
incubated overnight at 37C in 1.2 mg/ml solution of 5-bromo-4-
chloro-3-indolyl-b-D-galactopyranoside (X-gal; Invitrogen) in PBS
containing 5.2 mM potassium ferricyanide, 5.0 mM potassium
ferrocyanide, 1 mM magnesium chloride, 0.01% sodium deoxy-
cholic acid (sodium salt) and 0.02% IGEPAL CA-630. All chemicals
were from Sigma Aldrich. After staining, joints were rinsed with
PBS and ﬁxed in 10% normal buffered formalin (NBF) overnight
followed by decalciﬁcation in buffered formic acid (trisodium
citrate) (Decal, Polyscientiﬁc). Samples were embedded into
parafﬁn, sectioned coronally at three levels (100 mm apart) and
stained with hematoxylin and eosin (H&E), nuclear fast red or
toluidine blue (T. blue). Joints that received AAV1/HO-1 or control
vector were ﬁxed for 2 days in 10% NBF, decalciﬁed for 3 days,
embedded in parafﬁn and sections obtained were stainedwith H&E
Fig. 1. Histopathological scoring of joints from STR/ort and CBA mice at 26e31 weeks
of age. Scatter plot shows cartilage scores (H&E-stained sections) for individual joints
(ﬁlled circles) and group median (horizontal line) (n ¼ 8/group). Scoring was per-
formed as described in Methods. Statistical analysis by KruskaleWallis showed no
signiﬁcant difference between the STR/ort groups while they were signiﬁcantly
different from CBA mice (P < 0.05).
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fast red-stained sections analyzing three different levels. For joint
pathology scoring (H&E- and T. blue-stained sections) the section
with the most advanced histologic lesions was analyzed using
a published scoring system24. All evaluations were performed byAAV2/LacZA
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Fig. 2. Localization of AAV transduction sites in mouse joints after IA delivery of various rAA
in the mouse joints (sp, suprapatellar pouch) (B) Identiﬁcation of b-gal positive cell types in
type indicated. Analysis was performed 5 weeks after AAV administration using nuclear faa board-certiﬁed veterinary pathologist. Each analysis contained
n ¼ 8e12 STR/ort or CBA joints.
Immunohistochemisty
Tissue sections (5 mm) were processed for immunohistochem-
istry (IHC) using rabbit polyclonal antibodies to 3-nitrotyrosine
(3-NT; 1 mg/ml; Upstate Biotechnology) or to HO-1 (1:100 dilu-
tion; Epitomics) as previously described14. The signal from bio-
tinylated secondary goat anti-rabbit antibodies was ampliﬁed by
addition of avidinealkaline phosphatase conjugate (ABC System;
Vector Laboratories). The complex was revealed with Vector Red
(Vector Laboratories) followed by counterstaining with hematox-
ylin (Dako). All samples were run simultaneously for each antigen
to avoid experimental variation. Isotype controls were used in
parallel to conﬁrm the speciﬁcity of the staining. The number of
3-NT positive cells was scored using scoring system previously
described14. For HO-1 detection in synovial tissues, scoring was
done as follows: 0 ¼ no staining; 0.5 ¼ slight or patchy staining;
1¼ faintly stained cells; 1.5¼ uniform staining with a few intensely
stained cells; 2¼ uniform staining withmost cells stained intensely
and 3 ¼ uniform staining with all cells showing intense staining.
All IHC slides were evaluated by board-certiﬁed veterinary
pathologists.
Statistical analysis
Comparison of quantitative and semi-quantitative in vivo data
between multiple groups was performed using non-parametricAAV8/LacZ AAV1/EV (CBA)
AAV1/LacZ (CBA)AAV1/EV
AAV5/LacZ
STR/ort
AAV8/LacZ
STR/ort
Chondrocytes
Synovium
Adipocytes
Joint capsule
Skeletal
muscle
V serotypes with LacZ. (A) Macroscopic analysis for localization of b-gal positive tissues
each joint (n ¼ 8/group). Bar graph indicates the number of joints positive for the cell
st-stained joint sections.
S. Kyostio-Moore et al. / Osteoarthritis and Cartilage 21 (2013) 358e367 361KruskaleWallis test with Dunn’s multiple comparison post-test
using GraphPad Prism statistical software version 5.04 (GraphPad
Software, Inc.). Comparison of two groups was done by Manne
Whitney t test. In vitro data represented two to three
independent observations and were performed minimum of two
times. Data was analyzed for 95% conﬁdence intervals (CI) and
signiﬁcance by unpaired Student’s t test.
Results
Localization of AAV transduction in osteoarthritic joints
To evaluate tropism of rAAV serotypes in mouse OA joints,
a panel of pseudotyped AAV vectors encoding the LacZ gene was
administered directly into the stiﬂe joints of STR/ort mouse. These
mice develop spontaneously articular cartilage changes character-
istic for OA pathology around 10e20 weeks of age25. Histopatho-
logical scoring of joints at the time of sacriﬁce showed that all STR/
ort mice had detectable cartilage surface ﬁbrillations and loss ofFig. 3. Histological analysis for localization of rAAV transduction in osteoarthritic STR/ort a
Images show entire joint (40) and higher magniﬁcations (400) of skeletal muscle, synoviu
AAV2/LacZ (inset shows synovial lining in suprapatellar region), AAV5/LacZ, AAV8/LacZ and A
to 400). Abbreviations: tp, tibial plateau; fc, femoral condyle; sy, synovium; sp, suprapateproteoglycan while cartilage of CBA mice was normal (Fig. 1). To
localize AAV transduction sites, the joints were stained for b-gal
activity. Macroscopically, the most widespread staining around the
joint space was observed with rAAV1 for STR/ort and CBA mice
[Fig. 2(A)]. AAV8 strongly transduced muscle tissue surrounding
the joint while very little staining was detected with AAV5. Inter-
estingly, a distinctive suprapatellar pouch staining was consistently
detected with AAV2 capsid.
To identify transduced cell types in the mouse joint, nuclear fast
red-stained sections were scored for b-gal positive cells [Fig. 2(B)].
Control AAV1/EV injected joints showed no endogenous b-gal
activity while multiple cell types were positive in AAV1/LacZ-
treated STR/ort mice. These included synoviocytes, adipocytes,
joint capsule ﬁbroblasts, skeletal muscle cells and occasionally
chondrocytes (mainly at the sites of cartilage remodeling) of OA
joints (Fig. 3). AAV1 transduction was similar in CBA mice except
that chondrocytes were not transduced suggesting that OA-related
changes may aid AAV1. AAV5 showed a similar localization of
transduction but at a lower frequency. In AAV2-treated mice, tissuend normal CBA mouse joints. Top two panels: STR/ort joint infected with AAV1/LacZ.
m, adipose tissue, joint capsule and cartilage. Bottom two panels: STR/ort infected with
AV1/EV or CBA joint infected with AAV1/LacZ. Magniﬁcations for each are shown (40
llar pouch; ad, adipose tissue: jc, joint capsule and ac, articular cartilage.
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at the synovial lining while little staining was detected surrounding
the joint space. AAV8 exhibited mostly skeletal muscle trans-
duction with no detectable transduction in the synovial tissues.
Synovial oxidative stress and effect on AAV transduction
Oxidative stress is elevated in human OA synovial tissues. To
determine the effect of oxidative stress on AAV transduction, we
infected primary rabbit synoviocytes with rAAV2 encoding EGFP
gene followed by induction of oxidative stress by a brief exposure to
H2O2 (rabbit synoviocytes were used since mouse synoviocytes
were difﬁcult to obtain in sufﬁcient quantities; AAV2 was used for
rabbit cells due to better infection in vitro; data not shown). H2O2
has been detected in OA synoviocytes and generates strong
oxidizing agents including peroxinitrite28. These conditions
enhanced AAV transduction of synoviocytes in a dose-dependent
manner and resulted in 10-fold increase of EGFP expression with
100 mM H2O2 [Fig. 4(A)]. Generation of oxidizing agents was
conﬁrmed using cell permeable ROS sensitive ﬂuorescein dye (APF)
that reacts with hydroxyl radicals and peroxynitrite anions and
upon oxidation exhibits elevated green ﬂuorescence [Fig. 4(B)]29.
Synoviocyte viability was not reduced by 100 mM H2O2-treatmentFig. 4. Effect of oxidative stress on AAV transduction in primary synoviocytes in vitro.
Primary rabbit synoviocytes were infected with AAV2/EGFP followed by 2 h H2O2-
treatment as described in Methods and all endpoints were measured 3 days later.
(A) AAV transduction by percentage of EGFP-positive cells and median ﬂuorescence
intensity (MFI) by FACS analysis. The levels represent mean  95% CI (n ¼ 3/treatment;
P values by Student’s t test). (B) Effect of transient H2O2-treatment on intracellular ROS
levels. Cells were treated with H2O2 for 2 h and ROS levels were determined using ROS
sensitive ﬂuorescent probe, APF. The histogram shows comparable increase in ﬂuo-
rescence intensity with 50 and 100 mΜ H2O2. All experiments were performed
minimum of two times.as measured by trypan blue staining while higher concentrations of
H2O2 resulted in cell toxicity (not shown).
We next investigated the level of oxidative stress in STR/ort OA
joints and its correlation to AAV transduction sites in OA joints. The
localization and intensity of oxidative stress was evaluated by im-
munostaining for 3-NT, a marker for nitrosative and oxidative
stress. 3-NT modiﬁcations of cellular proteins are generated by
reaction with peroxynitrite (ONOOe), a reactive oxidant that forms
in the presence of nitric oxide and superoxide12. A signiﬁcant
increase in the number of 3-NT positive cells was observed in the
synovium of STR/ort mice compared to OA-resistant CBA mice
(Fig. 5). Increase in 3-NT staining was also detected in periosteum
while the number of 3-NT immunopositive cells in the cartilage,
ligaments and meniscus was not signiﬁcantly increased compared
to that in CBA joints. Thus, the synovium of STR/ort mice exhibits
signiﬁcantly elevated levels of oxidative stress that can potentially
increase AAV transduction in these cells.
AAV1-mediated HO-1 gene transfer into osteoarthritic joints
The above studies indicate that AAV1 is best suited for trans-
duction of mouse OA joint and that there is an increased oxidativeCBASTR/ort
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Fig. 5. Localization of oxidative stress in mouse stifﬂe joints. (A) 3-NT immunostaining
in osteoarthritic STR/ort (left panel) and normal CBA joints (right panel). Joint sections
from 4 month-old mice were subjected to 3-NT IHC as described in Methods. Repre-
sentative images (400magniﬁcation) of 3-NT immunostaining (red) in the synovium,
cartilage and periosteum are shown (synovium is indicated with an arrow; bn ¼ bone;
P ¼ periosteum). (B) Quantitation of 3-NT immunostaining in the mouse joints. Each
STR/ort (n ¼ 7e8) and CBA (n ¼ 3) joint was scored for the number of 3-NT positive
cells as described in Methods. Scatter plot shows scores for individual joints (ﬁlled
circles), group median (horizontal line) and P values (ManneWhitney test).
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stress on OA pathology, we generated a rAAV1 vector to deliver
a gene for human HO-1, a protein with anti-oxidant properties. The
expression and function of HO-1 from the AAV1 vector was
conﬁrmed in vitro. Delivery of this vector to 293 cells resulted in
a robust intracellular production of HO-1 protein [Fig. 6(A)]. It’s
production was further elevated by a transient H2O2-treatment
similar to results obtained with rabbit synoviocytes (data not
shown). Uninfected or AAV1/EV-treated cells had no detectable
HO-1. Approximately 10% of the total HO-1 was detected in
conditioned media despite the lack of signal peptide in the human
HO-1 protein suggesting a non-conventional secretion pathway.
The ability of HO-1 to reduce intracellular oxidative stress was
shown by reduction in APF ﬂuorescence in the AAV1/HO-1-treated
cells compared to that of cells treated with AAV1/EV indicating that
the vector was functional [Fig. 6(B)].
To evaluate the efﬁcacy of AAV1/HO-1 in the mouse OA model,
the vector was administered directly into the joints of STR/ort mice
at 3e4 months of age (dose similar to AAV/LacZ studies). Three
months later, the effect of local HO-1 expression in the joints on
cartilage degradation was analyzed by scoring the articular carti-
lage for surface changes (H&E-stained sections) and for proteo-
glycan content (T. blue-stained sections). The results showed
cartilage degradation in all the negative controls (AAV1/EV-treated)
and naive STR/ort mice mice compared to OA-resistant CBA mice
(Fig. 7). However, administration of AAV1/HO-1 into the STR/ort
joints did not signiﬁcantly reduce cartilage pathology compared to0
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Fig. 6. Production and potency of HO-1 from an AAV1/HO-1 vector in vitro. 293 cells
were infected with AAV1/HO-1. (A) HO-1 levels in conditioned media and cell lysates 3
days after infection by ELISA assay. (B) Effect of HO-1 production on intracellular ROS
accumulation. The ability of HO-1 to reduce oxidative stress was determined using
a ROS sensitive ﬂuorescent probe, APF, added after transient H2O2-treatment 3 days
post-AAV/HO-1 infection. The values represent mean  95% CI (n ¼ 3e6/treatment;
P values by Student’s t test). All experiments were performed minimum of two times.AAV1/EV-treated mice. No differences were observed in the syno-
vial inﬂammation or proliferation scores indicating that IA delivery
of rAAV1 vector did not affect synovial pathology (Fig. 7). No
treatment-related adverse effects were observed in these studies
(in bodyweight gain or mortalities).
Since no efﬁcacy was observed by the AAV1/HO-1 treatment, we
analyzed transduction efﬁciency of rAAV1 vectors by an IHC assay
to detect HO-1 or by X-gal staining (in AAV1/LacZ-administered
joints tested in parallel). Since speciﬁc detection of vector-
mediated production of human HO-1 by IHC was not possible
due to lack of human-speciﬁc HO-1 antibodies, the overall HO-1
levels in the joints were evaluated using an antibody that cross-
reacts with human and mouse HO-1. The results showed a signiﬁ-
cant increase in the synovial HO-1 expression in AAV1/EV-treated
STR/ort joints compared to CBA joints [Fig. 8(A and B)]. Due to
the robust endogenous, disease-induced HO-1 expression in STR/
ort mice, we were unable to measure any increase in HO-1 levels in
AAV1/HO-1-treated mice. However, AAV1/LacZ-treated joints
showed detectable b-gal activity in the synovial tissues 3 months
post-delivery therefore supporting successful rAAV-mediated gene
transfer in this experiment [Fig. 8(C)].
Discussion
Treatment of an osteoarthritic joint by local production of
a therapeutic agent is an attractive treatment strategy for OA. In this
report, we demonstrate that AAV-based vectors allowed gene
delivery into mouse OA joints. Our studies also highlighted a strong
elevation of oxidative stress in the synovial lining of the joint and
the beneﬁt of even a low level of oxidative stress to enhance
transduction of AAV vectors. We were, however, unable to observe
any signiﬁcant improvement from local expression of HO-1, an anti-
oxidant protein, on OA cartilage pathology indicating that this
delivery method or timing of the treatment was not sufﬁcient to
reduce the progression of pre-existing disease in the STR/ort model.
AAV vectors are useful tools for both systemic and localized
delivery of therapeutic genes due to their low inﬂammatory nature
and their ability to confer persistent transgene expression3e9,26,27.
They have also been tested in human joints in a clinical trial where
rAAV2 vectors were delivered intra-articularly into RA patients and
were well tolerated with no major safety issues30,31. To evaluate
rAAV vectors in animal models, the choice of capsid serotype is of
importance as the tissue tropism of AAV vector is affected by AAV
capsid serotype, species of the model as well as disease-induced
changes3,6,7,9,10. No previous studies have analyzed AAV trans-
duction in vivo in mouse OA joints where the synovium generally
exhibits only low and intermittent inﬂammation compared to RA
joints13,14. Based on our results, the use of AAV1 capsid resulted in
the most robust transduction of mouse OA joint providing gene
transfer to multiple cell types including synovial lining whereas
AAV5, AAV8 and AAV2 were not as efﬁcient. Contrary to these
results, others have reported that rAAV5 is the optimal serotype for
transduction of synovial lining in mouse models of RA with some
transduction occurring with AAV2 as well5e8. Currently it is unclear
whether the serotype differences in joint transduction reﬂect
disparities in the disease pathology or AAV receptor levels between
the models. Both AAV1 and AAV5 bind cell surface N-linked a2,3
and a2,6 sialic acids as primary attachment receptor unlike AAV2
which utilizes heparin sulfate proteoglycans for attachment32e34.
AAV1 is also known to efﬁciently transduce mouse muscle as was
seen in our data as well as human polarized airway epithelial
cells9,10,35. We observed very little in vivo gene transfer to mouse
chondrocytes by any of the AAV vectors tested. In vitro, transduction
of human and rabbit chondrocytes by AAV2 vectors has been re-
ported but this likely reﬂects differences in biological barriers
Fig. 7. Cartilage evaluation after local delivery of AAV1/HO-1 into mouse OA joints. rAAV vectors were administered by IA route into mouse joints at 3e4 months of age and articular
cartilage morphology was analyzed 3 months later. H&E-stained sections were scored for cartilage degradation, synovial inﬂammation and synovial proliferation. T. blue-stained
sections were scored for cartilage proteoglycan content. Scatter plot (n ¼ 8e12/group) shows cartilage scores for individual joints (ﬁlled circles) and group median (horizontal line)
as described in Methods. Statistical analysis by KruskaleWallis showed no difference between the STR/ort groups while they were all different from CBA mice (P < 0.05).
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vector delivery demonstrated limited access into subchondral bone
precluding these vectors for treating the OA bone pathology that
likely contributes to cartilage degradation.
The impact of disease environment on AAV transduction has
been previously demonstrated in joint diseases. Inmousemodels of
RA with a chronic inﬂammatory milieu in the joints, both higher
levels and better persistence of AAV transduction were observed in
RA compared to non-arthritic joints6. The beneﬁcial effect of
inﬂammation on AAV transductionwas also supported by increased
synovial ﬁbroblast transduction by addition of inﬂammatory cyto-
kines in vitro and by lipopolysaccharide (LPS)-treatment in vivo38,39.
Our in vitro data indicated that even low level of oxidative stress
augmented AAV transduction as this was achieved without
reducing cell viability or inducing endogenous HO-1 stress
response. Since the level of oxidative stress controlled the magni-
tude rAAV transgene expression in vitro, it may provide analogous
disease-inducible regulation of transgene production preferentially
at the sites of oxidative stress in vivo. Enhanced AAV transduction
has also been reported following UV irradiation and chemotherapy,
conditions that are likely to increase oxidative stress40.
While oxidative stress has been reported in STR/ort joints, we
demonstrated here elevated levels of peroxynitrite modiﬁed
proteins indicative of reactive oxygen and nitrogen species in the
synovial lining of the joints13,14. Previously, we have observed
another indicator of oxidative stress, advanced glycation end-
products (AGEs), also strongly increased in the synovium of these
mice14. Both the reactive oxygen and nitrogen species and their
products induce stress signaling, apoptosis and inﬂammatory
pathways such as NF-kB, MAPK and ERK1/2 in OA that result in
elevation of inﬂammatory cytokines and cartilage degrading
proteases1,12,25. The signiﬁcance of these pathways in OA pathology
were supported by studies using RNA-mediated interference of the
NF-kB pathway that slowed-down the progression of OA ina surgical model of rat OA41. Synovial oxidative stress and inﬂam-
mation were also recently reported to be predictive both for OA
pain and cartilage degradation in human OA patients17. Thus,
synovial oxidative stress represents an attractive target for thera-
peutic intervention to test its role as a driver of OA pathology.
HO-1 exhibits multiple beneﬁcial properties including anti-
oxidant, anti-inﬂammatory and cytoprotective functions and is
often endogenously induced by various stress stimuli18,19,43,44. It
has been detected in human OA synovium, cartilage and synovial
ﬂuids42e44. In both OA and RA animal models in vivo, systemic
induction of HO-1 by pharmacological agents reduced inﬂamma-
tion and disease pathology20,21,45. In vitro, HO-induction in OA
chondrocytes enhanced cell viability and anabolic processes while
it reduced apoptosis and catabolic processes such as matrix met-
alloprotease (MMP) and prostaglandin production22. Similarly, HO-
1 expression in osteoarthritic synoviocytes after lentiviral vector
delivery down-regulated MMP-1 and -2 production and reduced
translocation of HMGB-1, a mediator of synovitis23. All of these
inﬂammatory markers and MMPs are elevated in the joints of STR/
ort mice1,14,24. However, in contrast to HO-1 beneﬁts in systemic or
in vitro settings, our data showed that the local production of HO-1
in the diseased joints did not reduce cartilage degradation in the
mouse OA model. Instead, we detected endogenous elevation of
HO-1 levels in the synovial tissues from OA mice similar to obser-
vations on increased HO-1 in synovial joint tissues from human OA
and RA patients42e44. The synovial HO-1 was likely induced by the
strong nitrosative and oxidative stress detectable already at
5 weeks of age in these mice13,14,46. Peroxynitrite-induced HO-1
expression has also been observed in articular chondrocytes and
other cell types in vitro47,48. Though the highly oxidative milieu was
beneﬁcial for AAV transduction, it is unknown how it affects the
function of locally produced proteins. Both glycation and tyrosine
nitration modiﬁed proteins are present in the synovium of these
mice14. Additional studies would be required to determinewhether
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Fig. 8. Analysis of HO-1 expression in mouse synovial tissues 3 months after vector delivery. (A) HO-immunostaining for osteoarthritic STR/ort and normal CBA joints. Joint sections
(n ¼ 8e12/group) were stained as described in Methods. Representative HO-1 immunostaining (red) in the synovium of each group and isotype control antibody for STR/ort with
AAV1/HO-1 are shown (matching joint). All isotype antibody controls were negative for growth plate staining while sections treated with HO-1 antibody stained endogenous HO-1
in the growth plate area (solid arrow; positive control for the HO-1 staining in all joints). (B) Scoring of synovial HO-1 immunostaining in the mouse joints. Scatter plot shows values
for each STR/ort and CBA joint (n ¼ 8e12/group) scored as described in Methods. Statistical analysis by KruskaleWallis showed no difference between the STR/ort treatment groups
while both groups were different from CBA mice (P < 0.05). (C) AAV transgene expression from AAV1/LacZ in STR/ort mice 3 months after vector delivery. X-gal treated joints were
sectioned and stained with nuclear fast (red) and location of b-gal activity (blue) was analyzed. Location of synovium is shown by arrows. Abbreviations: sy, synovium; fc, femoral
condyle; tp, tibial plateau (magniﬁcation: top panel, 40; bottom panel, 400).
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subject to modiﬁcations in vivo as suggested by the inactivation of
catalytic activity of HO-1 by peroxynitrite in vitro49. Alternatively,
our lack of efﬁcacy with HO-1 may suggest that active treatment in
models during ongoing disease is likely to be a higher hurdle than
more commonly used prophylactic in vivo or in vitro models.
In summary, the present study demonstrates that mouse
synovial tissues are amenable to transduction by rAAV1 after
delivery into the joint space. We also showed signiﬁcantly
elevated levels of the oxidative stress in synovial lining which is
likely to increase AAV-based vector transduction in vivo thus
making synovial lining cells into disease-inducible depot organs
for local therapeutic protein production. However, the local
production of HO-1 was not sufﬁcient to reduce articular cartilage
degradation suggesting either a minor role of synovial oxidative
stress on OA cartilage pathology or issues in therapeutic protein
synthesis and function in the highly oxidative environment.
Furthermore, the limited access of current AAV vectors by IA
delivery to areas such as chondrocytes and subchondral bone mayrepresent a challenge in their utility for delivery of therapeutics
designed to improve cartilage viability and repair necessary for
the treatment of OA.
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